Falutz and colleagues, 2007
The New England Journal of Medicine report of the 26-week placebo-controlled trial in 412 adults with HIV. It supports the visceral-fat comparison used on these pages. Its results concern that population and do not establish a general weight-loss indication.
Read the publication · DOI: 10.1056/NEJMoa072375
Falutz and colleagues, 2008
The AIDS publication following treatment over 52 weeks and examining what happened after discontinuation. It supplies the distinction between a reduction maintained during treatment and fat returning after treatment ends. That follow-up is important when interpreting a short-term scan result.
Read the publication · DOI: 10.1097/QAD.0b013e32830a5058
Stanley and colleagues, 2014
The JAMA randomized study of 50 adults with HIV receiving antiretroviral treatment. It measured both visceral fat and a hepatic lipid-to-water outcome over six months. The liver measure has a different definition from the relative fat-fraction result in the later trial.
Read the publication · DOI: 10.1001/jama.2014.8334
Stanley and colleagues, 2019
The Lancet HIV trial involving 61 adults with HIV and fatty liver over 12 months. It is the source for the relative hepatic-fat-fraction reduction and the proportions reaching a low liver-fat threshold. The paper leaves longer-term tissue outcomes for further study.
Read the publication · DOI: 10.1016/S2352-3018(19)30338-8
Fourman and colleagues, 2020
The JCI Insight analysis of liver-tissue gene activity in HIV-associated fatty liver. It describes energy-production, inflammatory, and tissue-remodeling pathways. These findings are possible biological correlates of the measured fat response; they are not proof of a durable reduction in serious liver illness.
Read the publication · DOI: 10.1172/jci.insight.140134
Lake and colleagues, 2021
The AIDS analysis of CT density in visceral and subcutaneous fat. It supports the reported 26-week changes in Hounsfield units and the separation of tissue density from quantity. The paper provides a specific imaging meaning for fat quality rather than a complete measure of health.
Read the publication · DOI: 10.1097/QAD.0000000000002897
Stanley and colleagues, 2011, inflammatory markers
The AIDS paper examining inflammatory and related markers alongside visceral-fat changes in adults with HIV. It helps frame the distinction between measurements that change together and a direct treatment effect on a particular pathway. An association is not a separate clinical indication.
Read the publication · DOI: 10.1097/QAD.0b013e328347f3f1
Stanley and colleagues, 2011, hormone responses
The Journal of Clinical Endocrinology and Metabolism experiment in 13 healthy men over two weeks. It examines growth hormone secretion, IGF-1, and insulin sensitivity. Its mechanistic purpose and short follow-up differ from the larger trials evaluating abdominal fat in adults with HIV.
Read the publication · DOI: 10.1210/jc.2010-1587
Gonzalez-Sales and colleagues, 2015
The Journal of Pharmacokinetics and Pharmacodynamics analysis connecting tesamorelin exposure with hormone responses. It supports the discussion of pharmacokinetics and pharmacodynamics as related but different processes. A population model cannot determine an amount or timing instruction for a reader.
Read the publication · DOI: 10.1007/s10928-015-9416-2
National Library of Medicine, 2026, Egrifta WR
The DailyMed prescribing information for Egrifta WR, effective July 29, 2026 in the record consulted here. It supplies the approved indication, contraindications, glucose and IGF-1 cautions, formulation distinction, and the reported elimination half life. It is product information rather than a trial publication.
National Library of Medicine, 2026, Egrifta SV
The DailyMed prescribing information for Egrifta SV, effective July 29, 2026 in the consulted record. Read it as the label for that specific formulation. Its existence beside the WR label is not a basis for swapping preparations or transferring amounts from one label to another.
Food and Drug Administration, application record
The Drugs@FDA record for application 022505 documents tesamorelin approval and its later status as a biologics license application. It is used for regulatory history rather than an efficacy estimate. A product record cannot establish a use beyond the indication in its prescribing information.
Food and Drug Administration, compounding questions
The agency explains the limits of drug-compounding exemptions and the separate position of biological products. This source supports the access distinction on the comparison and dosage pages. It does not turn a prescription assessment into approval of any proposed preparation or use.
Food and Drug Administration, 2013 notice
The Federal Register notice addresses the discontinued Geref products and the finding that withdrawal from sale was not for safety or effectiveness reasons. That narrow regulatory conclusion does not make a current compounded preparation an approved medicine or demonstrate superiority against tesamorelin.